查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046297

心搏過緩治療設備市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、設備、最終用戶、地區和競爭格局分類，2021-2031年

Bradycardia Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Devices, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球心搏過緩治療設備市場預計將大幅擴張，從 2025 年的 100.9 億美元成長到 2031 年的 138.7 億美元，複合年成長率為 5.45%。

這些植入式醫療系統旨在持續監測心率，並在心率低於臨界閾值時提供電刺激。市場擴張的主要促進因素是全球人口老化，這與房室傳導阻滯等傳導系統疾病發病率的增加以及需要持續治療性介入的合併心血管疾病盛行率的上升直接相關。

市場概覽
預測期 2027-2031
市場規模：2025年 100.9億美元
市場規模：2031年 138.7億美元
複合年成長率：2026-2031年 5.45%
成長最快的細分市場 竇性心搏過緩
最大的市場 北美洲

市場促進因素

心臟節律器系統的技術進步正在從根本上改變市場格局，克服了傳統經靜脈植入式設備的臨床限制。一個關鍵趨勢是向無導線心律調節器（包括雙腔系統）的轉變，這種心律調節器消除了導線斷裂和囊袋感染等併發症，同時提高了患者的舒適度和恢復時間。隨著領先製造商將產品系列過渡到這些新一代設備，這項創新正在直接影響市場表現。例如，雅培的節律管理部門在2024年第三季實現了7%的成長，這主要得益於AVEIR無導線心律調節器的強勁市場接受度。同時，心血管疾病盛行率的不斷上升仍然是推動心搏過緩治療需求持續成長的主要動力。隨著全球人口老化，傳導系統疾病和心律不整的發生率不斷增加，需要更多的器械干預來維持血流動力學穩定。根據美國心臟協會2024年的統計數據，光是在美國，預計就有1.279億成年人將患有某種形式的心血管疾病，凸顯了對心律管理解決方案的迫切需求。這一情況也反映在整個行業的積極發展趨勢中，波士頓科學公司循環系統部門累計，2024年第三季淨銷售額達21.29億美元。

市場挑戰

全球心搏過緩治療設備市場面臨許多挑戰，主要包括植入後併發症，如感染疾病和導線脫落。這些併發症往往需要進行高風險且成本高昂的再次手術。這些不利事件從根本上阻礙了市場成長，增加了長期治療成本，並引發了法律責任的擔憂，這可能阻礙植入式治療方法的普及。當設備失效或發生感染疾病時，所需的再次手術通常比初次植入更為複雜，且耗費的資源也更多，從而降低了這些心律不整管理方案的整體經濟效益。近期的手術數據也印證了這項挑戰的嚴峻性。例如，德國胸腔心臟血管外科協會報告稱，2024年總合進行了20114例心律調節器和植入式心臟整流去顫器 ）手術，這表明即使併發症率較低，也存在相當數量的「再次手術」。與初次植入相比，這些再次手術的死亡率和經濟負擔總是更高，從而給醫院預算帶來壓力，並影響市場擴張。

市場趨勢

臨床上向傳導起搏技術的重大轉變正在重新定義植入策略，其重點在於生理性心室活化而非傳統的右心室心尖起搏。這種方法，特別是利用希氏束或左束支區域的起搏，可降低起搏誘發心肌病的風險，並維持長期的心臟同步。製造商正在積極檢驗其現有導線產品線的有效性，以滿足日益成長的生理性起搏解決方案的電生理需求，例如，波士頓科學公司於2024年9月獲得FDA核准，其INGEVITY+起搏導線獲批用於傳導起搏，擴大了適應症範圍。同時，人工智慧演算法的整合正在提高診斷準確性，從而應對與持續心臟監測相關的數據過載這一重大挑戰。由於植入式心臟監測器會產生大量資料集，人工智慧已被證明對於過濾訊號雜訊和顯著減少假陽性通知至關重要，這些假陽性通知經常會對臨床工作流程造成巨大壓力。這項技術的整合使醫生能夠專注於真正需要關注的心律不整事件，從而提高診斷的準確性和操作效率。正如Medtronic在2024年5月宣布的那樣，先進的AccuRhythm人工智慧演算法已被證實可將心房顫動和心臟麻痹的誤報率降低高達85%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球心搏過緩治療設備市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（竇性心搏過緩、竇性停搏、病竇症候群、心搏過緩症候群、心臟傳導阻滯）
    • 裝置類型（心律調節器{單腔心律調節器、雙腔心律調節器}、去心房顫動）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美心搏過緩治療器材市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲心搏過緩治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區心搏過緩治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲心搏過緩治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲心搏過緩治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球心搏過緩治療設備市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • Osypka Medical GmbH
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Nihon Kohden Corporation
  • Medico SRL
  • Zoll Medical Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16869

The Global Bradycardia Treatment Devices Market is anticipated to expand significantly, projected to grow from USD 10.09 Billion in 2025 to USD 13.87 Billion by 2031, at a Compound Annual Growth Rate (CAGR) of 5.45%. These implantable medical systems are designed to continuously monitor cardiac rhythm and deliver electrical impulses when the heart rate drops below a critical threshold. The market's primary expansion is driven by the globally aging population, which directly correlates with an increased incidence of conduction system disorders like atrioventricular block, and the rising prevalence of concurrent cardiovascular conditions necessitating consistent therapeutic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.09 Billion
Market Size 2031USD 13.87 Billion
CAGR 2026-20315.45%
Fastest Growing SegmentSinus Bradycardia
Largest MarketNorth America

Market Driver

Technological advancements in cardiac pacemaker systems are fundamentally reshaping the market, addressing previous clinical limitations of traditional transvenous implants. A significant trend is the shift towards leadless pacing options, including dual-chamber systems, which eliminate complications such as lead fractures and pocket infections while simultaneously improving patient comfort and recovery times. This innovation directly translates into enhanced financial performance for major manufacturers as they transition their product portfolios to these next-generation devices, as exemplified by Abbott's Rhythm Management segment achieving 7% growth in Q3 2024, largely driven by the strong adoption of the AVEIR leadless pacemaker. Concurrently, the rising prevalence of cardiovascular diseases remains a foundational catalyst for the sustained demand for bradycardia therapies. As the global population ages, the incidence of conduction system disorders and arrhythmias increases, necessitating a higher volume of device interventions to maintain hemodynamic stability. The American Heart Association's 2024 statistics estimated approximately 127.9 million adults in the United States alone had some form of cardiovascular disease, underscoring the critical need for rhythm management solutions, which is reflected in the robust activity of the broader sector, with Boston Scientific's Cardiology division generating $2.129 billion in net sales in Q3 2024.

Market Challenge

The Global Bradycardia Treatment Devices Market faces a substantial obstacle in the form of post-implantation complications, predominantly infections and lead dislodgement, which often necessitate risky and expensive repeat surgeries. These adverse events fundamentally hinder market growth by inflating the long-term cost of care and introducing liability concerns that can deter the adoption of implantable therapies. When a device fails or an infection occurs, the required revision procedure is typically more complex than the initial implantation, consuming a disproportionate amount of healthcare resources and diminishing the overall economic efficiency of these rhythm management solutions. The scale of this challenge is evident in recent procedural volumes; for instance, the German Society for Thoracic and Cardiovascular Surgery reported a total of 20,114 pacemaker and implantable cardioverter-defibrillator procedures in 2024, indicating that even a fractional complication rate results in a significant number of "redo" operations. Such procedures are consistently identified as carrying higher mortality rates and financial burdens compared to primary implants, thus straining hospital budgets and affecting market expansion.

Market Trends

A significant clinical shift towards conduction system pacing techniques is redefining implantation strategies by prioritizing physiological ventricular activation over traditional right ventricular apical pacing. This approach, specifically utilizing His bundle or left bundle branch area pacing, mitigates the risk of pacing-induced cardiomyopathy and preserves long-term cardiac synchrony, with manufacturers actively validating their existing lead portfolios to meet the growing electrophysiological demand for physiological pacing solutions, as demonstrated by Boston Scientific's September 2024 FDA approval to expand the indication of its INGEVITY+ pacing leads for conduction system pacing. Concurrently, the integration of AI algorithms for enhanced diagnostic accuracy is addressing the critical challenge of data overload associated with continuous cardiac monitoring. As insertable cardiac monitors generate vast datasets, artificial intelligence proves essential for filtering signal noise and significantly reducing the burden of false-positive notifications that frequently overwhelm clinical workflows. This technological integration ensures physicians can focus solely on actionable arrhythmia events, thereby improving diagnostic confidence and operational efficiency, as Medtronic's May 2024 announcement showed advanced AccuRhythm AI algorithms reducing false alerts for atrial fibrillation and pause episodes by up to 85%.

Key Market Players

  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • MicroPort Scientific Corporation
  • Osypka Medical GmbH
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Nihon Kohden Corporation
  • Medico S.R.L.
  • Zoll Medical Corporation

Report Scope

In this report, the Global Bradycardia Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bradycardia Treatment Devices Market, By Type

  • Sinus Bradycardia
  • Sinus Pause
  • Sick Sinus Syndrome
  • Tachy-brady Syndrome
  • Heart Block

Bradycardia Treatment Devices Market, By Devices

  • Pacemakers
  • Defibrillator

Bradycardia Treatment Devices Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Bradycardia Treatment Devices Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bradycardia Treatment Devices Market.

Available Customizations:

Global Bradycardia Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bradycardia Treatment Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Sinus Bradycardia, Sinus Pause, Sick Sinus Syndrome, Tachy-brady Syndrome, Heart Block)
    • 5.2.2. By Devices (Pacemakers {Single Chamber Pacemaker, Dual Chamber Pacemaker}, Defibrillator)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Bradycardia Treatment Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Devices
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bradycardia Treatment Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Devices
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Bradycardia Treatment Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Devices
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Bradycardia Treatment Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Devices
        • 6.3.3.2.3. By End User

7. Europe Bradycardia Treatment Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Devices
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bradycardia Treatment Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Devices
        • 7.3.1.2.3. By End User
    • 7.3.2. France Bradycardia Treatment Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Devices
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Bradycardia Treatment Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Devices
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Bradycardia Treatment Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Devices
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Bradycardia Treatment Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Devices
        • 7.3.5.2.3. By End User

8. Asia Pacific Bradycardia Treatment Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Devices
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bradycardia Treatment Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Devices
        • 8.3.1.2.3. By End User
    • 8.3.2. India Bradycardia Treatment Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Devices
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Bradycardia Treatment Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Devices
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Bradycardia Treatment Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Devices
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Bradycardia Treatment Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Devices
        • 8.3.5.2.3. By End User

9. Middle East & Africa Bradycardia Treatment Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Devices
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bradycardia Treatment Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Devices
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Bradycardia Treatment Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Devices
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Bradycardia Treatment Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Devices
        • 9.3.3.2.3. By End User

10. South America Bradycardia Treatment Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Devices
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bradycardia Treatment Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Devices
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Bradycardia Treatment Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Devices
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Bradycardia Treatment Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Devices
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bradycardia Treatment Devices Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Medtronic plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories
  • 15.3. Boston Scientific Corporation
  • 15.4. Biotronik SE & Co. KG
  • 15.5. MicroPort Scientific Corporation
  • 15.6. Osypka Medical GmbH
  • 15.7. Lepu Medical Technology (Beijing) Co., Ltd.
  • 15.8. Nihon Kohden Corporation
  • 15.9. Medico S.R.L.
  • 15.10. Zoll Medical Corporation

16. Strategic Recommendations

17. About Us & Disclaimer